Low Prevalence of RET Rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in Sporadic Papillary Thyroid Carcinomas in Taiwan Chinese
- 1 April 2005
- journal article
- Published by Mary Ann Liebert Inc in Thyroid®
- Vol. 15 (4), 326-335
- https://doi.org/10.1089/thy.2005.15.326
Abstract
Somatic rearrangement of the tyrosine kinase receptor RET is restricted to papillary thyroid carcinoma (PTC). The prevalence of RET/PTC1, RET/PTC2, and RET/PTC3 has been found to vary between 0% and 20% in most series of sporadic (nonradiation-induced) PTCs analyzed by type-specific reverse transcription-polymerase chain reaction (RT-PCR) alone. However, high prevalence reported from Taiwan (6 out of 11, 55%) indicates RET rearrangement is an important genetic lesion underlying the development of PTC in Taiwan. Because the high prevalence of RET rearrangements in Chinese patients was particularly striking, we were prompted to reexamine chimeric transcripts of RET/PTC1, RET/PTC2, and RET/PTC3 using the same experimental designs in a larger number of cases in the same population. RT-PCR was performed to amplify fusion products of RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET from frozen tissue of 105 sporadic PTCs. RT-PCR was also performed with two different primer sets for RET/PTC1, RET/PTC2, and RET/PTC3 followed by Southern hybridization in the first 62 tumors. In our study, RET/PTC1, RET/PTC2, and RET/PTC3 oncogenes were found in only 7 of 105 (7%) sporadic PTCs. Of these tumors, 3 involved RET/PTC1 and 4 involved RET/PTC3. No RET/PTC2 rearrangements were observed. In the first 62 tumor samples, another two different primer sets for each rearrangement also gave concordant results. Furthermore, application of Southern hybridization in these 62 PTCs did not identify additional tumor harboring RET chimeric transcripts. We identified one tumor as having an ELKS-RET rearrangement (1 of 105, 1%). In conclusion, we detected RET rearrangements in 8 of 105 (8%) sporadic PTCs in Taiwan, a much lower prevalence than previously reported for this population but comparable to those reported in other nations using similar methodology. RET chimeric oncogenes only account for a small fraction of PTCs in Taiwan.Keywords
This publication has 35 references indexed in Scilit:
- The RET proto-oncogene in human cancersOncogene, 2000
- RET/PTC and RET Tyrosine Kinase Expression in Adult Papillary Thyroid CarcinomasJournal of Clinical Endocrinology & Metabolism, 1998
- Expression of Ret/PTC1, -2, -3, -Δ3 and -4 in German papillary thyroid carcinomaBritish Journal of Cancer, 1998
- High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiationOncogene, 1997
- ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?Journal of Clinical Endocrinology & Metabolism, 1996
- Ret and trk proto-oncogene activation in thyroid papillary carcinomas in french patients from the champagne-ardenne regionClinical Biochemistry, 1996
- The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2Genes, Chromosomes and Cancer, 1994
- A t( 10; 17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinomaGenes, Chromosomes and Cancer, 1994
- Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.JCI Insight, 1992
- Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC.Proceedings of the National Academy of Sciences of the United States of America, 1992